Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Immunogenicities of Env glycoproteins from circulating HIV-1 isolates in China focusing on the strategy of "DNA prime plus protein boost".

Wang Z, Wang SX, Liu SY, Bao ZY, Zhuang DM, Li L, Zhang CH, Zhang L, Li JY, Lu S.

Chin Med J (Engl). 2009 Oct 5;122(19):2339-45.

PMID:
20079137
2.

Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.

Richmond JF, Mustafa F, Lu S, Santoro JC, Weng J, O'Connell M, Fenyö EM, Hurwitz JL, Montefiori DC, Robinson HL.

Virology. 1997 Apr 14;230(2):265-74.

3.

Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.

Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, Liu Q, Whitney S, Keen T, Nair BC, Kalyanaraman VS, Markham P, Lu S.

Virology. 2006 Jun 20;350(1):34-47. Epub 2006 Apr 17.

4.

DNA prime-protein boost using subtype consensus Env was effective in eliciting neutralizing antibody responses against subtype BC HIV-1 viruses circulating in China.

Zhang M, Zhang L, Zhang C, Hong K, Shao Y, Huang Z, Wang S, Lu S.

Hum Vaccin Immunother. 2012 Nov 1;8(11):1630-7. doi: 10.4161/hv.21648. Epub 2012 Oct 30.

5.

Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.

Townsley S, Mohamed Z, Guo W, McKenna J, Cleveland B, LaBranche C, Beaumont D, Shen X, Yates NL, Pinter A, Tomaras GD, Ferrari G, Montefiori DC, Hu SL.

J Virol. 2016 Sep 12;90(19):8644-60. doi: 10.1128/JVI.00853-16. Print 2016 Oct 1.

6.

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.

Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, Blanchard J, Wang S, Mboudjeka I, Leung L, Lian Y, Fong A, Buckner C, Ly A, Hilt S, Ulmer J, Wild CT, Mascola JR, Stamatatos L.

J Virol. 2001 Jun;75(12):5526-40.

7.

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, Fisch DC, Ketas T, Yuste E, Desrosiers RC, Klasse PJ, Maddon PJ, Olson WC, Moore JP.

Virology. 2007 Apr 10;360(2):329-40. Epub 2006 Nov 28.

8.

HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.

Bower JF, Li Y, Wyatt R, Ross TM.

Vaccine. 2006 Jun 29;24(26):5442-51. Epub 2006 Apr 3.

PMID:
16621193
9.

Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy.

Stambas J, Brown SA, Gutierrez A, Sealy R, Yue W, Jones B, Lockey TD, Zirkel A, Freiden P, Brown B, Surman S, Coleclough C, Slobod KS, Doherty PC, Hurwitz JL.

Vaccine. 2005 Mar 31;23(19):2454-64.

PMID:
15752831
11.

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.

Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, Vancott TC, Huang Y, Chakrabarti BK, Kong WP, Yang ZY, Xu L, Montefiori DC, Nabel GJ, Letvin NL.

J Virol. 2005 Jan;79(2):771-9.

12.

DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice.

Rasmussen RA, Ong H, Kittel C, Ruprecht CR, Ferrantelli F, Hu SL, Polacino P, McKenna J, Moon J, Travis B, Ruprecht RM.

Vaccine. 2006 Mar 20;24(13):2324-32. Epub 2005 Dec 19. Erratum in: Vaccine. 2006 Jun 5;24(23):5092. Policano, Patricia [corrected to Polacino, Patricia].

PMID:
16406147
13.
14.

Eliciting broad neutralizing antibody to HIV-1: envelopes of different lentivirus cross immunization by prime-boost vaccination.

Luo Z, Ren L, Zheng Y, Qi Z, Liang H, Liu Y, Hong K, Shao Y.

Vaccine. 2012 Aug 3;30(36):5316-23. doi: 10.1016/j.vaccine.2012.06.053. Epub 2012 Jun 27.

PMID:
22749599
15.

Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen.

Leung L, Srivastava IK, Kan E, Legg H, Sun Y, Greer C, Montefiori DC, zur Megede J, Barnett SW.

AIDS. 2004 Apr 30;18(7):991-1001.

PMID:
15096801
16.
17.

Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination.

Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, Binley J, Lu S.

J Virol. 2008 Aug;82(15):7369-78. doi: 10.1128/JVI.00562-08. Epub 2008 May 21.

20.

DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.

Buonaguro L, Devito C, Tornesello ML, Schröder U, Wahren B, Hinkula J, Buonaguro FM.

Vaccine. 2007 Aug 10;25(32):5968-77. Epub 2007 Jun 11.

PMID:
17629365

Supplemental Content

Support Center